<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02264405</url>
  </required_header>
  <id_info>
    <org_study_id>EBMT-8410015</org_study_id>
    <nct_id>NCT02264405</nct_id>
  </id_info>
  <brief_title>Autologous SCT for Progressive Systemic Sclerosis: a Prospective NIS Study</brief_title>
  <acronym>NISSC</acronym>
  <official_title>Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis: a Prospective Non-Interventional Approach Across Europe (NISSC) for the Autoimmune Diseases Working Party of the EBMT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Group for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Group for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effectiveness of Autologous Hematopoietic Stem Cell transplantation (AHSCT) for
      early severe or rapidly progressive Systemic Sclerosis (SSc) as currently performed by
      different study protocols used across Europe in various EBMT centres through the careful
      recording and analysis of routinely collected clinical and biological data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Different protocols are used in the different centres, it is not yet clear which approach
      will be the most efficient and the safest. Every centre will follow its own local protocol
      for AHSCT which usually refers to the recent update of the EBMT Guidelines for HSCT in
      autoimmune disease. Patient selection for AHSCT treatment technique with regard to the
      risk/benefit balance has to be carefully addressed by standard patient pretransplant
      evaluation, whereas treatment local regimen, follow-ups evaluation, supportive medication and
      prophylaxis will be recorded and analysed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 year post transplant</time_frame>
    <description>Progression free survival (PFS), defined as survival since Baseline (the 1st day of mobilisation) without evidence of progression of SSc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>2 year post transplant</time_frame>
    <description>Treatment related toxicity throughout the study period using WHO toxicity parameters (expressed as maximum grade toxicity per organ system, see appendix) Incidence of Adverse Events (AE) and Serious Adverse Events (SE) Neutrophil and platelet engraftment, defined as first day after transplantation with absolute neutrophil count &gt; 500 cells/μL and &gt;20.000 platelets/μL without platelet transfusion, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 year post transplant</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>at 1 year post transplant</time_frame>
    <description>Response to treatment within 1 year following autologous HSCT, defined as
25% improvement in mRSS (modified Rodnan Skin Score) and/or
≥10% improvement in Diffuse Capacit y for carbon monoxyde (DLCO) or F^rced Vital Capacity (FVC) as compared to baseline without need of further immunosuppression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Quality of life</measure>
    <time_frame>2 year post transplant</time_frame>
    <description>Assessed by SHAQ (Scleroderma Health Assessment Questionnaire) evolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse incidence</measure>
    <time_frame>2 year post transplant</time_frame>
    <description>Defined as any of the following changes after prior response to treatment on quarterly follow up as defined below:
Worsening of mRSS &gt; 25%
New/Worsening of organ manifestation: lungs, heart or kidney</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100-day Treatment related mortality</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>any death during 100 day following transplant that cannot be attributed to progression or relapse of the disease</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>NISSC</arm_group_label>
    <description>Autologous HSCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous HSCT</intervention_name>
    <description>1st AHSCT</description>
    <arm_group_label>NISSC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with autologous HSCT for severe systemic sclerosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Autologous HSCT

          -  Age between 18 and 65 years at time of transplant.

          -  Established diagnosis of progressive systemic sclerosis according to ARA-criteria

        Exclusion Criteria:

          -  Pregnancy or inadequate contraception

          -  Severe concomitant disease

          -  Reduced lung function

          -  Previously damaged bone marrow

          -  Uncontrolled severe infection

          -  Severe concomitant psychiatric illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Farge, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>EBMT ADWP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuela Badoglio</last_name>
    <phone>+33.1.70.64.24.16</phone>
    <email>manuela.badoglio@upmc.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominique Farge, PhD</last_name>
    <email>dominique.farge-bancel@sls.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Badoglio Manuela- EBMT Paris Office</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Badoglio</last_name>
      <phone>+33.1.70.64.24.16</phone>
      <email>manuela.badoglio@upmc.fr</email>
    </contact>
    <contact_backup>
      <last_name>Dominique Farge, PhD</last_name>
      <phone>+33 (0)1 40 27 46 13</phone>
      <email>dominique.farge-bancel@sls.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Dominique Farge, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joerg Henes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans Ulrich Scherer, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John A Snowden, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicoletta Del Papa, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Moore, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://ebmt.org</url>
    <description>Organisation website</description>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>October 17, 2014</last_update_submitted>
  <last_update_submitted_qc>October 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune diseases</keyword>
  <keyword>Systemic sclerosis</keyword>
  <keyword>Autologous Hematopoietic stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

